Treatment of stage D2 prostatic carcinoma with combined gonadal and adrenal suppression in a 60-year-old man.
A 60-year-old man with stage D2 prostatic carcinoma received treatment with a new luteinizing hormone-releasing hormone superagonist. After a seven-month remission; relapse of the disease occurred and an adrenal-suppressing dose of dexamethasone was added. The resulting combined gonadal and adrenal suppression led to another remission that lasted five months. This case supports other observations of the importance of adrenal androgen production in the pathobiology of prostatic carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D003907:Dexamethasone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017274:Nafarelin; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D013997:Time Factors
D017274:Nafarelin; D007987:Gonadotropin-Releasing Hormone; D003907:Dexamethasone